Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

CEO

Mr. Paul Lévesque

Zamestnanci

103

Krajina

Kanada

ISIN

CA88338H1001

Zalistovania

TQ8.MU

0 Comments

Podeľ sa o svoj názor

FAQ

Aký ticker má akcia spoločnosti Theratechnologies?▼

Ticker akcie sa môže líšiť podľa burzy. Napríklad na burze sa akcie spoločnosti Theratechnologies obchodujú pod tickerom TQ8.MU.

Koľko má Theratechnologies zamestnancov?▼

Ku dňu júla 08, 2026 má spoločnosť 103 zamestnancov.

Do akého sektora patrí Theratechnologies?▼

Theratechnologies pôsobí v sektore Health & Wellness.

Kedy spoločnosť Theratechnologies uskutočnila split akcií?▼

Spoločnosť Theratechnologies v poslednom čase neuskutočnila žiadny split akcií.

Kde má Theratechnologies sídlo?▼

Theratechnologies má sídlo v meste Montreal, Kanada.